SAFETY OF ROXADUSTAT VERSUS ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATMENT OF ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE INCIDENT TO OR NOT RECEIVING DIALYSIS: POOLED ANALYSIS OF FOUR PHASE 3 STUDIES - Université de Picardie Jules Verne Accéder directement au contenu
Article Dans Une Revue Nephrology Dialysis Transplantation Année : 2022

SAFETY OF ROXADUSTAT VERSUS ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATMENT OF ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE INCIDENT TO OR NOT RECEIVING DIALYSIS: POOLED ANALYSIS OF FOUR PHASE 3 STUDIES

Domaines

Médecine humaine et pathologie

Louise DESSAIVRE  : Connectez-vous pour contacter le contributeur

https://u-picardie.hal.science/hal-03732942

Soumis le : jeudi 21 juillet 2022-10:40:16

Dernière modification le : mercredi 22 mars 2023-11:44:12

Fichier non déposé

Dates et versions

hal-03732942 , version 1 (21-07-2022)

Identifiants

  • HAL Id : hal-03732942 , version 1

Citer

Jonathan Barratt, Frank Dellanna, Jose Portoles, Gabriel Choukroun, Luca de Nicola, et al.. SAFETY OF ROXADUSTAT VERSUS ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATMENT OF ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE INCIDENT TO OR NOT RECEIVING DIALYSIS: POOLED ANALYSIS OF FOUR PHASE 3 STUDIES. Nephrology Dialysis Transplantation, 2022, 37 (3), pp.I387-I388. ⟨hal-03732942⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

U-PICARDIE MP3CV
31 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More